NO20090783L - Pyrimidonforbindelser som inhibitorer av GSK-3 - Google Patents
Pyrimidonforbindelser som inhibitorer av GSK-3Info
- Publication number
- NO20090783L NO20090783L NO20090783A NO20090783A NO20090783L NO 20090783 L NO20090783 L NO 20090783L NO 20090783 A NO20090783 A NO 20090783A NO 20090783 A NO20090783 A NO 20090783A NO 20090783 L NO20090783 L NO 20090783L
- Authority
- NO
- Norway
- Prior art keywords
- gsk
- inhibitors
- pyrimidone compounds
- pyrimidone
- derivatives
- Prior art date
Links
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title abstract 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000008318 pyrimidones Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82326706P | 2006-08-23 | 2006-08-23 | |
| PCT/IB2007/002390 WO2008023239A1 (en) | 2006-08-23 | 2007-08-13 | Pyrimidone compounds as gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090783L true NO20090783L (no) | 2009-03-13 |
Family
ID=38670755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090783A NO20090783L (no) | 2006-08-23 | 2009-02-18 | Pyrimidonforbindelser som inhibitorer av GSK-3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100292205A1 (de) |
| EP (1) | EP2057141B1 (de) |
| JP (1) | JP2010501540A (de) |
| KR (1) | KR20090052884A (de) |
| CN (1) | CN101528729A (de) |
| AT (1) | ATE530540T1 (de) |
| AU (1) | AU2007287319A1 (de) |
| CA (1) | CA2661334C (de) |
| ES (1) | ES2373587T3 (de) |
| IL (1) | IL197080A0 (de) |
| MX (1) | MX2009001913A (de) |
| NO (1) | NO20090783L (de) |
| WO (1) | WO2008023239A1 (de) |
| ZA (1) | ZA200901037B (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101809021B (zh) | 2007-09-11 | 2013-04-24 | 雅培制药有限公司 | 八氢-吡咯并[3,4-b]吡咯n-氧化物 |
| EP2138488A1 (de) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen |
| AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| JP5442852B2 (ja) | 2009-08-13 | 2014-03-12 | 田辺三菱製薬株式会社 | タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EA024099B1 (ru) | 2010-09-13 | 2016-08-31 | Оцука Фармасьютикал Ко., Лтд. | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина |
| EP2681215B1 (de) | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serin-/threoninkinaseinhibitoren |
| US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| PL2797888T3 (pl) | 2011-12-31 | 2016-12-30 | Połączone związki tricykliczne jako inhibitory kinazy raf | |
| DK2820009T3 (en) | 2012-03-01 | 2018-04-16 | Array Biopharma Inc | Serine / threonine kinase inhibitors |
| TW201408658A (zh) | 2012-08-27 | 2014-03-01 | Array Biopharma Inc | 絲胺酸／酥胺酸激酶抑制劑 |
| PL2970890T3 (pl) | 2013-03-14 | 2020-11-16 | The Brigham And Women's Hospital, Inc. | Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych |
| EP3189134A1 (de) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Zusammensetzungen, systeme und verfahren zur erzeugung von innenohrhaarzellen zur behandlung von gehörverlust |
| CN113307805A (zh) | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018098411A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Gsk-3 inhibitors |
| EP3562827A1 (de) | 2016-12-30 | 2019-11-06 | Frequency Therapeutics, Inc. | 1h-pyrrol-2,5-dion-verbindungen und verfahren zur verwendung davon zur induktion der selbsterneuerung von unterstützenden stamm-/vorläuferzellen |
| HUE070649T2 (hu) | 2017-10-19 | 2025-06-28 | Teijin Pharma Ltd | Benzimidazol-származékok és felhasználásuk |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法 |
| EP3920885A1 (de) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen |
| CN113666878A (zh) * | 2021-08-27 | 2021-11-19 | 宁夏常晟药业有限公司 | 一种5-溴-2-氯嘧啶-4-羧酸甲酯的合成方法 |
| IL314895A (en) * | 2022-02-16 | 2024-10-01 | Duke Street Bio Ltd | Pharmaceutical compound |
| EP4522606A1 (de) * | 2022-05-13 | 2025-03-19 | Merck Sharp & Dohme LLC | Inhibitoren des humanen respiratorischen synzytialvirus und des metapneumovirus |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1136489A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperidin-1-yl]pyrimidinonderivate |
| EP1136493A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidon-, 2-(Furopyridinyl)pyrimidon-2-(isoquinolinyl)pyrimidon-, 2-(Pyridoindolyl)pyrimidon- und 2-(Benzofuropyridinyl)pyrimidonderivate |
| EP1136482A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer |
| WO2001070727A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
| EP1136099A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidonderivate als GSK3beta-Hemmer |
| EP1136491A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Heteroarylalkylamino]pyrimidonderivate |
| EP1136483A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidonderivate |
| IL160701A0 (en) * | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| IL160700A0 (en) * | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| CN1726209B (zh) * | 2002-12-16 | 2011-04-13 | 三菱制药株式会社 | 3-取代的-4-嘧啶酮衍生物 |
| TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| US20070117818A1 (en) * | 2004-02-04 | 2007-05-24 | Masaichi Hasegawa | Pyrimidinone compounds useful as kinase inhibitors |
| AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| CN101048397A (zh) * | 2004-09-29 | 2007-10-03 | 三菱制药株式会社 | 作为τ蛋白激酶1抑制剂的6－（吡啶基）－4－嘧啶酮衍生物 |
-
2007
- 2007-08-13 CN CNA2007800394073A patent/CN101528729A/zh active Pending
- 2007-08-13 AU AU2007287319A patent/AU2007287319A1/en not_active Abandoned
- 2007-08-13 KR KR1020097005783A patent/KR20090052884A/ko not_active Ceased
- 2007-08-13 CA CA2661334A patent/CA2661334C/en not_active Expired - Fee Related
- 2007-08-13 EP EP07789659A patent/EP2057141B1/de not_active Not-in-force
- 2007-08-13 ES ES07789659T patent/ES2373587T3/es active Active
- 2007-08-13 MX MX2009001913A patent/MX2009001913A/es not_active Application Discontinuation
- 2007-08-13 JP JP2009525121A patent/JP2010501540A/ja not_active Withdrawn
- 2007-08-13 AT AT07789659T patent/ATE530540T1/de not_active IP Right Cessation
- 2007-08-13 WO PCT/IB2007/002390 patent/WO2008023239A1/en not_active Ceased
- 2007-08-13 US US12/438,198 patent/US20100292205A1/en not_active Abandoned
-
2009
- 2009-02-13 ZA ZA200901037A patent/ZA200901037B/xx unknown
- 2009-02-17 IL IL197080A patent/IL197080A0/en unknown
- 2009-02-18 NO NO20090783A patent/NO20090783L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2373587T3 (es) | 2012-02-06 |
| US20100292205A1 (en) | 2010-11-18 |
| ATE530540T1 (de) | 2011-11-15 |
| EP2057141A1 (de) | 2009-05-13 |
| IL197080A0 (en) | 2009-11-18 |
| KR20090052884A (ko) | 2009-05-26 |
| WO2008023239A1 (en) | 2008-02-28 |
| MX2009001913A (es) | 2009-03-06 |
| CN101528729A (zh) | 2009-09-09 |
| ZA200901037B (en) | 2010-04-28 |
| EP2057141B1 (de) | 2011-10-26 |
| CA2661334A1 (en) | 2008-02-28 |
| JP2010501540A (ja) | 2010-01-21 |
| CA2661334C (en) | 2011-11-29 |
| AU2007287319A1 (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090783L (no) | Pyrimidonforbindelser som inhibitorer av GSK-3 | |
| NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
| NO20090596L (no) | Antivirale fosfinatforbindelser | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| WO2009024611A3 (en) | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
| EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
| MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
| GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
| MY148634A (en) | Pyridazinone derivatives | |
| NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
| WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| GEP20146197B (en) | New compounds | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| BR112012002134B8 (pt) | compostos inibidores de apaf-1 | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| SMT201300109B (it) | Imidazopiridazincarbonitrili utili come inibitori di chinasi | |
| SV2010003650A (es) | INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA | |
| DK2089369T3 (da) | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme | |
| NO20084328L (no) | Nye forbindelser | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |